Details for Patent: 10,314,788
✉ Email this page to a colleague
Which drugs does patent 10,314,788 protect, and when does it expire?
Patent 10,314,788 protects MORPHABOND ER and ROXYBOND and is included in two NDAs.
This patent has twenty-three patent family members in ten countries.
Summary for Patent: 10,314,788
Title: | Pharmaceutical compositions configured to deter dosage form splitting |
Abstract: | An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequivalent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided. |
Inventor(s): | Shah; Manish S. (Valley Cottage, NY), Difalco; Ray J. (Valley Cottage, NY) |
Assignee: | INSPIRION DELIVERY SCIENCES LLC (Basking Ridge, NJ) |
Application Number: | 13/058,757 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 10,314,788
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-001 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-002 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-003 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
Ohemo Life | MORPHABOND ER | morphine sulfate | TABLET, EXTENDED RELEASE;ORAL | 206544-004 | Oct 2, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,314,788
PCT Information | |||
PCT Filed | February 12, 2009 | PCT Application Number: | PCT/US2009/033919 |
PCT Publication Date: | February 18, 2010 | PCT Publication Number: | WO2010/019279 |
International Family Members for US Patent 10,314,788
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2008286914 | ⤷ Sign Up | |||
Australia | 2009282376 | ⤷ Sign Up | |||
Australia | 2015200009 | ⤷ Sign Up | |||
Australia | 2017200414 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |